Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2025-09-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于冻干带状疱疹病毒mRNA疫苗临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the acceptance of their clinical trial application for a freeze-dried shingles virus mRNA vaccine by the National Medical Products Administration. It includes details about the product, application, and regulatory acceptance notice. The document is short (946 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-19 Chinese
关于子公司向银行申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company about its subsidiary applying for a bank credit facility. It details the credit amount, purpose, and approvals from the board and supervisory committee. There are no financial statements, earnings data, or detailed financial analysis. The document is short (1212 characters) and focuses on financing activities. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the correct classification is CAP.
2025-08-25 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 31st meeting of the 5th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes multiple agenda items such as approval of the 2025 semi-annual report, fundraising usage report, asset impairment provisions, credit facility application, profit distribution proposal, amendments to foreign exchange transaction management, and a related party transaction involving minority equity transfer. The document contains voting results and references to further detailed reports available on the regulatory disclosure website. It is a formal board meeting resolution announcement rather than the full semi-annual report or financial statements themselves. The document length is 3223 characters, which is relatively short and consistent with a board meeting resolution announcement. Therefore, the filing type corresponds to Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-08-25 Chinese
关于全资子公司完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a business registration change for a wholly-owned subsidiary, including details about capital increase and company information updates. It does not contain financial statements, audit information, or detailed financial results. It is a corporate announcement about a capital increase and registration update, which fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2025-08-25 Chinese
关于2025年半年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from a company regarding its 2025 half-year profit distribution plan. It includes details about the board and supervisory committee's approval, independent directors' opinions, and the proposed dividend payout per share. The document explicitly states that the profit distribution plan will be submitted to the shareholders' meeting for approval. The content focuses on dividend distribution details rather than presenting full financial statements or comprehensive financial performance data. The document length is relatively short (2368 characters), and it serves as a formal announcement of a dividend plan rather than a full financial report or interim report. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder information.
2025-08-25 Chinese
2025年上半年募集资金存放与实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled "云南沃森生物技术股份有限公司 2025 年上半年募集资金存放与实际使用情况专项报告," which translates to "Yunnan Watson Biotechnology Co., Ltd. 2025 First Half Year Special Report on the Deposit and Actual Use of Raised Funds." The content extensively details the amounts of funds raised through share issuance, their deposit in special accounts, usage for various investment projects, changes in project implementation, temporary use of idle funds for liquidity, and compliance with regulatory requirements. It includes detailed financial figures related to fundraising and usage up to June 30, 2025. The document is a specialized report focusing on the management and use of capital raised by the company, not a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial data about fundraising and capital use, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-08-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.